Invokana Clinical Trials

A checklist icon
 

Invokana Clinical Trials

Key Studies

Click on a clinical study below:

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
Perkovic V, Jardine MJ, Neal B, et al.
The New England Journal of Medicine 2019;380(24):2295-2306

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V, de Zeeuw D, Mahaffey KW, et al.
The Lancet Diabetes & Endocrinology 2018;6(9):691-704

Kidney disease and increased mortality risk in type 2 diabetes.
Afkarian M, Sacha M, Kestenbaum B, et al.
Journal of the American Society of Nephrology 2013;24(2):302-308

Invokana vs other SGLT2 inhibitors

Click on a clinical study below:

Consistent reductions in HbA1c with Invokana 100 mg and 300 mg

Click on a clinical study below:

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Forst T, Guthrie R, Goldenberg R, et al.
Diabetes, Obesity & Metabolism 2014;16(5):467-477

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP, Charpentier G, Hollander P, et al.
International Journal of Clinical Practice 2013;67(12):1267-1282

Safety and tolerability

Click on a clinical study below:

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.